In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden discuss why alongside the rising popularity of glucagon-like peptide 1 (GLP-1)-based medications for obesity, there are also concerns about side effects, long-term outcomes, and unregulated products. This evidence concerns the gene GLP1R and obesity disorder.